Bioenergetic-based neuroprotection and glaucoma

Clinical and Experimental Ophthalmology

Volumn 36, Issue 4, 2008, Pages 377-385

  Schober, Michael S ^a   Chidlow, Glyn ^a   Wood, John P M ^a   Casson, Robert J ^a  

^a South Australian Institute of Ophthalmology   (Australia)

Author keywords

Bioenergetic neuroprotection; Excitotoxicity; Glaucoma

Indexed keywords

3 AMINOBENZAMIDE; CALCIUM ION; CREATINE; GLUCOSE; HEXOKINASE; LACTIC ACID; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NICOTINAMIDE; PLACEBO; UBIQUINONE;

APOPTOSIS; BIOENERGETIC NEUROPROTECTION; BRAIN ISCHEMIA; CELL ENERGY; CLINICAL TRIAL; DRUG MECHANISM; ENERGY EXPENDITURE; ENERGY METABOLISM; ENERGY RESOURCE; EXCITOTOXICITY; GLAUCOMA; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; HYPERGLYCEMIA; INTRAOCULAR PRESSURE; MUSCULAR DYSTROPHY; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OPEN ANGLE GLAUCOMA; OXIDATIVE STRESS; PARKINSON DISEASE; RETINA GANGLION CELL; RETINA ISCHEMIA; RETINA NERVE CELL; REVIEW; RISK FACTOR;

ANIMALS; CALCIUM; CELL DEATH; ENERGY METABOLISM; FREE RADICAL SCAVENGERS; GLAUCOMA; GLUCOSE; HUMANS; LACTIC ACID; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RETINA; RETINAL GANGLION CELLS;

EID: 47649107323     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2008.01740.x     Document Type: Review

References (122)

1. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
2. Casson RJ. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Experiment Ophthalmol 2006; 34: 54-63.
3. Osborne NN, Chidlow G, Wood JP, Schmidt KG, Casson R, Melena J. Expectations in the treatment of retinal diseases: Neuroprotection. Curr Eye Res 2001; 22: 321-32.
4. Osborne NN, Chidlow G, Wood J, Casson R. Some current ideas on the pathogenesis and the role of neuroprotection in glaucomatous optic neuropathy. Eur J Ophthalmol 2003; 13 (Suppl. 3): S19-26.
5. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
6. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-91.
7. Chidlow G, Wood JPM, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs 2007; 67: 725-59.
8. Baker SK, Tarnopolsky MA. Targeting cellular energy production in neurological disorders. Expert Opin Investig Drugs 2003; 12: 1655-79.
9. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 2003; 53 (Suppl. 3): S39-47; discussion S47-8.
10. Browne SE, Beal MF. The energetics of Huntington's disease. Neurochem Res 2004; 29: 531-46.
11. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 2004; 101: 10726-31.
12. Dedeoglu A, Kubilus JK, Yang L. et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 2003; 85: 1359-67.
13. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001; 49: 561-74.
14. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
15. Arend O, Plange N, Sponsel WE, Remky A. Pathogenetic aspects of the glaucomatous optic neuropathy: Fluorescein angiographic findings in patients with primary open angle glaucoma. Brain Res Bull 2004; 62: 517-24.
16. Wolf S, Arend O, Haase A, Schulte K, Remky A, Reim M. Retinal hemodynamics in patients with chronic open-angle glaucoma. Ger J Ophthalmol 1995; 4: 279-82.
17. Schulte K, Wolf S, Arend O, Harris A, Henle C, Reim M. Retinal hemodynamics during increased intraocular pressure. Ger J Ophthalmol 1996; 5: 1-5.
18. Mitchell P, Leung H, Wang JJ. et al. Retinal vessel diameter and open-angle glaucoma: The Blue Mountains Eye Study. Ophthalmology 2005; 112: 245-50.
19. Hall JK, Andrews AP, Walker R, Piltz-Seymour JR. Association of retinal vessel caliber and visual field defects in glaucoma. Am J Ophthalmol 2001; 132: 855-9.
20. Papastathopoulos KI, Jonas JB. Fluorescein angiographic correlation of focal narrowing of retinal arterioles in glaucoma. Br J Ophthalmol 1998; 82: 48-50.
21. Papastathopoulos KI, Jonas JB. Follow up of focal narrowing of retinal arterioles in glaucoma. Br J Ophthalmol 1999; 83: 285-9.
22. Beal MF. Mechanisms of excitotoxicity in neurologic diseases. FASEB J 1992; 6: 3338-44.
23. Casson RJ, Chidlow G, Wood JP, Osborne NN. The effect of hyperglycemia on experimental retinal ischemia. Arch Ophthalmol 2004; 122: 361-6.
24. Lopez L, Sannita WG. Glucose availability and the electrophysiology of the human visual system. Clin Neurosci (New York, NY) 1997; 4: 336-40.
25. Winkler B. A quantitative assessment of glucose metabolism in the isolated retina. In: Doly CY, Droy-LeFaix MT, eds. Les Seminaires Ophtalmologiques d'IPSEN: Vision et Adaptation. Amsterdam, The Netherlands: Elsevier, 1995; 78-96.
26. Winkler BS, Arnold MJ, Brassell MA, Sliter DR. Glucose dependence of glycolysis, hexose monophosphate shunt activity, energy status, and the polyol pathway in retinas isolated from normal (nondiabetic) rats. Invest Ophthalmol Vis Sci 1997; 38: 62-71.
27. Magistretti PJ, Pellerin L, Chatton JY, Pierre K. Energy on demand: A mechanism for astrocyte-neuron metabolic coupling. J Neurochem 2003; 85: 2.
28. Magistretti PJ, Sorg O, Yu NC, Martin JL, Pellerin L. Neurotransmitters regulate energy-metabolism in astrocytes -implications for the metabolic trafficking between neural cells. Dev Neurosci 1993; 15: 306-12.
29. Schurr A. Lactate, glucose and energy metabolism in the ischemic brain [review]. Int J Mol Med 2002; 10: 131-6.
30. Schurr A, Payne RS, Miller JJ, Rigor BM. Glia are the main source of lactate utilized by neurons for recovery of function posthypoxia. Brain Res 1997; 774: 221-4.
31. Schurr A, Payne RS, Miller JJ, Rigor BM. Brain lactate is an obligatory aerobic energy substrate for functional recovery after hypoxia: Further in vitro validation. J Neurochem 1997; 69: 423-6.
32. Poitry-Yamate CL, Poitry S, Tsacopoulos M. Lactate released by muller glial-cells is metabolized by photoreceptors from mammalian retina. J Neurosci 1995; 15: 5179-91.
33. Bergersen L, Johannsson E, Veruki ML. et al. Cellular and subcellular expression of monocarboxylate transporters in the pigment epithelium and retina of the rat. Neuroscience 1999; 90: 319-31.
34. Chidlow G, Wood JPM, Graham M, Osborne NN. Expression of monocarboxylate transporters in rat ocular tissues. Am J Physiol Cell Physiol 2005; 288: C416-C428.
35. Gerhart DZ, Leino RL, Drewes LR. Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience 1999; 92: 367-75.
36. Wood JPM, Chidlow G, Graham M, Osborne NN. Energy substrate requirements for survival of rat retinal cells in culture: The importance of glucose and monocarboxylates. J Neurochem 2005; 93: 686-97.
37. Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci 2005; 118: 5411-9.
38. Bristow EA, Griffiths PG, Andrews RM, Johnson MA, Turnbull DM. The distribution of mitochondrial activity in relation to optic nerve structure. Arch Ophthalmol 2002; 120: 791-6.
39. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001; 21: 1133-45.
40. Laughlin SB, van Steveninck RRD, Anderson JC. The metabolic cost of neural information. Nat Neurosci 1998; 1: 36-41.
41. Brandstatter JH, Koulen P, Wassle H. Diversity of glutamate receptors in the mammalian retina. Vision Res 1998; 38: 1385-97.
42. Pin JP, Duvoisin R. The metabotropic glutamate receptors - structure and functions. Neuropharmacology 1995; 34: 1-26.
43. Ames A, Li YY, Heher EC, Kimble CR. Energy-metabolism of rabbit retina as related to function - high cost of Na+ transport. J Neurosci 1992; 12: 840-53.
44. Ames A, Li YY. Energy-requirements of glutamatergic pathways in rabbit retina. J Neurosci 1992; 12: 4234-42.
45. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol 1957; 58: 193-201.
46. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
47. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185: 1481-6.
48. Nicotera P, Leist M, Ferrando-May E. Intracellular ATP, a switch in the decision between apoptosis and necrosis. Toxicol Lett 1998; 103: 139-42.
49. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
50. Richter C, Schweizer M, Cossarizza A, Franceschi C. Control of apoptosis by the cellular ATP level. FEBS Lett 1996; 378: 107-10.
51. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995; 36: 774-86.
52. Quigley HA. Ganglion cell death in glaucoma: Pathology recapitulates ontogeny. Aust N Z J Ophthalmol 1995; 23: 85-91.
53. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18: 39-57.
54. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol 1997; 115: 1031-5.
55. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol Lond 2003; 552: 335-44.
56. Boveris A. Determination of the production of superoxide radicals and hydrogen-peroxide in mitochondria. Methods Enzymol 1984; 105: 429-35.
57. Ohia SE, Opere CA, LeDay AM. Pharmacological consequences of oxidative stress in ocular tissues. Mutat Res 2005; 579: 22-36.
58. Tezel G. Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences. Prog Retin Eye Res 2006; 25: 490-513.
59. Izzotti A, Bagnis A, Sacca SC. The role of oxidative stress in glaucoma. Mutat Res Rev Mutat Res 2006; 612: 105-14.
60. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol 2007; 52: S162-S173.
61. Orrenius S, Nicotera P. The calcium ion and cell death. J Neural Transm Suppl 1994; 43: 1-11.
62. Cortassa S, Aon MA, Marban E, Winslow RL, O'Rourke B. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J 2003; 84: 2734-55.
63. McCormack JG, Halestrap AP, Denton RM. Role of calcium-ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 1990; 70: 391-425.
64. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341: 233-49.
65. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990; 13: 171-82.
66. Broderick R, Somlyo AP, Transport M. Calcium by in situ mitochondria - electron-probe analysis of vascular smooth-muscle. Circ Res 1987; 61: 523-30.
67. Murphy E, Jacob R, Lieberman M. Cytosolic free calcium in chick heart-cells - its role in cell injury. J Mol Cell Cardiol 1985; 17: 221-31.
68. Huser J, Rechenmacher CE, Blatter LA. Imaging the permeability pore transition in single mitochondria. Biophys J 1998; 74: 2129-37.
69. Isaev NK, Andreeva NA, Stel'mashuk EV, Zorov DB. Role of mitochondria in the mechanisms of glutamate toxicity. Biochem (Moscow) 2005; 70: 611-8.
70. Nicolli A, Petronilli V, Bernardi P. Modulation of the mitochondrial cyclosporine a-sensitive permeability transition pore by matrix ph -evidence that the pore open closed probability is regulated by reversible histidine protonation. Biochemistry 1993; 32: 4461-5.
71. Petronilli V, Cola C, Massari S, Colonna R, Bernardi P. Physiological effectors modify voltage sensing by the cyclosporine a-sensitive permeability transition pore of mitochondria. J Biol Chem 1993; 268: 21939-45.
72. Brdiczka D, Beutner G, Ruck A, Dolder M, Wallimann T. The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. BioFactors 1998; 8: 235-42.
73. Halestrap AP, Kerr PM, Javadov S, Woodfield KY. Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochimica Et Biophysica Acta-Bioenergetics 1998; 1366: 79-94.
74. Brustovetsky N, Klingenberg M. Mitochondrial ADP/ATP carrier can be reversibly converted into a large channel by Ca2+. Biochemistry 1998; 35: 8483-8.
75. Ruck A, Dolder M, Wallimann T, Brdiczka D. Reconstituted adenine nucleotide translocase forms a channel for small molecules comparable to the mitochondrial permeability transition pore. FEBS Lett 1998; 426: 97-101.
76. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 483-7.
77. Tsujimoto Y, Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 2000; 7: 1174-81.
78. Shimizu S, Konishi A, Kodama T, Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci USA 2000; 97: 3100-5.
79. Shimizu S, Shinohara Y, Tsujimoto Y. Bax and Bcl-x(L) independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator. Oncogene 2000; 19: 4309-18.
80. Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999; 20: 171-81.
81. Malcon C, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res 2000; 860: 195-8.
82. Lam TT. The effect of 3-aminobenzamide, an inhibitor of poly-ADP-ribose polymerase, on ischemia/reperfusion damage in rat retina. Res Commun Mol Pathol Pharmacol 1997; 95: 241-52.
83. Ji D, Li GY, Osborne NN. Nicotinamide attenuates retinal ischemia and light insults to neurones. Neurochem Int 2007; 52: 786-98.
84. Matthews RT, Yang LC, Browne S, Baik M, Beal MF. Coenzyme Q. 10) administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998; 95: 8892-7.
85. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q(10) attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged. Brain Res 1998; 783: 109-14.
86. Schulz JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q. 10) and Nicotinamide and a Free-Radical Spin Trap Protect against Mptp Neurotoxicity. Exp Neurology 1995; 132: 279-83.
87. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by coenzyme Q(10). Neurobiol Dis 2005; 18: 618-27.
88. Nucci C, Tartaglione R, Cerulli A. et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol 2007; 82: 397-406.
89. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes -early onset and effect of insulin. J Clin Invest 1998; 102: 783-91.
90. Henningsen C, Zahner G, Thaiss F. High glucose induces type 1 hexokinase gene expression in isolated glomeruli of diabetic rats and in mesangial cells. Nephron Physiol 2003; 93: 67-75.
91. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 2004; 377: 347-55.
92. Matthews RT, Yang LC, Jenkins BG. et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998; 18: 156-63.
93. Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther 2005; 108: 193-207.
94. Wallimann T, Hemmer W. Creatine-Kinase in nonmuscle tissues and cells. Mol Cell Biochem 1994; 133: 193-220.
95. Brdiczka D, Wallimann T. The importance of the outer mitochondrial compartment in regulation of energy-metabolism. Mol Cell Biochem 1994; 133: 69-83.
96. Prass K, Royl G, Lindauer U. et al. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J Cereb Blood Flow Metab 2007; 27: 452-9.
97. Wolosker H, deSouza DO, deMeis L. Regulation of glutamate transport into synaptic vesicles by chloride and proton gradient. J Biol Chem 1996; 271: 11726-31.
98. Xu CJ, Klunk WE, Kanfer JN, Xiong Q, Miller G, Pettegrew JW. Phosphocreatine-dependent glutamate uptake by synaptic vesicles -a comparison with ATP-dependent glutamate uptake. J Biol Chem 1996; 271: 13435-40.
99. Bender A, Auer DP, Merl T. et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005; 252: 36-41.
100. Schlegel J, Zurbriggen B, Wegmann G, Wyss M, Eppenberger HM, Wallimann T. Native mitochondrial creatine-kinase forms octameric structures. 1. Isolation of 2 interconvertible mitochondrial creatine-kinase forms, dimeric and octameric mitochondrial creatine-kinase -characterization, localization, and structure-function-relationships. J Biol Chem 1988; 263: 16942-53.
101. Jacobus WE, Lehninger AL. Creatine kinase of rat heart mitochondria: coupling of creatine phosphorylation to electron transport. J Biol Chem 1973; 248: 4803-10.
102. Rojo M, Hovius R, Demel RA, Nicolay K, Wallimann T. Mitochondrial creatine-kinase mediates contact formation between mitochondrial-membranes. J Biol Chem 1991; 266: 20290-5.
103. Stachowiak O, Dolder M, Wallimann T, Richter C. Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J Biol Chem 1998; 273: 16694-9.
104. Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta Mol Basis Dis 2006; 1762: 164-80.
105. O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett 1997; 414: 253-7.
106. Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T. Inhibition of the mitochondrial permeability transition by creatine kinase substrates -requirement for microcompartmentation. J Biol Chem 2003; 278: 17760-6.
107. Gideon P, Henriksen O, Sperling B. et al. Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke -a proton magnetic-resonance spectroscopy study. Stroke 1992; 23: 1566-72.
108. Lodi R, Schapira AHV, Manners D. etal. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-6.
109. Tarnopolsky MA, Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 1999; 22: 1228-33.
110. Brewer GJ, Wallimann TW. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem 2000; 74: 1968-78.
111. Juravleva E, Barbakadze T, Mikeladze D, Kekelidze T. Creatine enhances survival of glutamate-treated neuronal/glial cells, modulates ras/ NF-kappa B signaling, and increases the generation of reactive oxygen species. J Neurosci Res 2005; 79: 224-30.
112. Andres RH, Ducray AD, Huber AW. et al. Effects of creatine treatment on survival and differentiation of GABA-ergic neurons in cultured striatal tissue. J Neurochem 2005; 95: 33-45.
113. Andres RH, Huber AW, Schlattner U. et al. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience 2005; 133: 701-13.
114. Sullivan PG, Geiger JD, Mattson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Ann Neurol 2000; 48: 723-9.
115. Scheff SW, Dhillon HS. Creatine-enhanced diet alters levels of lactate and free fatty acids after experimental brain injury. Neurochem Res 2004; 29: 469-79.
116. Zhu S, Li M, Figueroa BE. et al. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J Neurosci 2004; 24: 5909-12.
117. Lensman M, Korzhevskii DE, Mourovets VO. et al. Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat. Brain Res 2006; 1114: 187-94.
118. Klivenyi P, Ferrante RJ, Matthews RT. et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med 1999; 5: 347-50.
119. Ferrante RJ, Andreassen OA, Jenkins BG. et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000; 20: 4389-97.
120. Matthews RT, Ferrante RJ, Klivenyi P. et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999; 157: 142-9.
121. Hersch SM, Gevorkian S, Marder K. et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006; 66: 250-2.
122. Bender A, Koch W, Elstner M. et al. Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology 2006; 67: 1262-4.